Latest Aortic valve replacement Stories
INDIANAPOLIS, April 11, 2013 /PRNewswire-USNewswire/ -- Franciscan St. Francis Health is the first hospital in the United States to implant a new device that could improve the quality of life for patients with aortic valve disease. The On-X® Aortic Prosthetic Valve with Anatomic Sewing Ring is the most advanced mechanical heart valve and first to address the important concern of distorting the adjacent structures within the heart. The innovative valve is the only mechanical valve...
Catheter-delivered aortic valve durable at 3 years All-cause and cardiovascular mortality were similar for transaortic valve replacement compared to open-heart surgery in high-risk older patients at three years with no increased risk of stroke after 30 days, according to results from the PARTNER study presented today at the American College of Cardiology's 62nd Annual Scientific Session. The transcatheter aortic valve replacement (TAVR) system was investigated as an alternative to...
DUBLIN, March 8, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/fhjghw/transcatheter) has announced the addition of the "TransCatheter Aortic Valves Market" report to their offering. The global transcatheter aortic heart valve opportunity continues to be strong and growing. Edwards reported 2012 sales of $552 and predicts it will manage to generate $780 million globally in 2013, including $420 million in the US alone. Our analysts...
Clinical trial to determine if chest closure device leads to better bone healing following cardiac surgery KANSAS CITY, Mo., Feb. 25, 2013 /PRNewswire-USNewswire/ -- Patients undergoing open heart procedures such as coronary artery bypass or valve surgery may be eligible to enroll in a clinical trial available in the Kansas City area only at Saint Luke's Mid America Heart Institute. The SternaLock® Blu clinical trial will compare patients whose sternum (breastbone) is closed with...
New Procedure Provides Lifesaving Treatment For Previously Inoperable Patients HACKENSACK, N.J., Dec. 13, 2012 /PRNewswire-USNewswire/ -- Hackensack University Medical Center is the only hospital in New Jersey performing transcatheter aortic valve replacement (TAVR) via both transfemoral and transapical delivery. The transapical delivery method is a minimally invasive replacement of aortic heart valves through a small incision in the chest. Hackensack University Medical Center was...
Although current guidelines recommend 3 months of anticoagulation treatment after bioprosthetic aortic valve replacement surgery, a study that included more than 4,000 patients found that patients who had warfarin therapy continued between 3 and 6 months after surgery had a lower rate of cardiovascular death, according to a study in the November 28 issue of JAMA. "Biological prostheses are preferred to mechanical valves for aortic valve replacement (AVR) surgery in elderly patients older...
Results of PARTNER Cohort B trial presented at TCT 2012 A study found that transcatheter aortic valve replacement (TAVR) yielded lower mortality rates after three years compared with medical therapy in patients deemed to be ineligible for conventional aortic valve surgery. Results of the PARTNER Cohort B trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the...
NATICK, Mass., Oct. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) further demonstrated the strength of its structural heart program today at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation with four podium presentations showcasing the potential of the WATCHMAN(®) Left Atrial Appendage Closure (LAAC) Device and the Lotus(TM) Aortic Valve System to provide improved treatment...
BETHLEHEM, Pa., Oct. 22, 2012 /PRNewswire/ -- Micro Interventional Devices, Inc.(TM) (MID), an emerging cardiovascular medical device company, announced today that the first patient has been treated using its self-sealing, cardiac access and closure technology, Permaseal(TM). The patient is the first to be enrolled in the company's STASIS clinical trial that has commenced in Europe. The first STASIS case was performed by Principal Investigator Professor Dr. med. Rudiger Lange,...
More Patients Now Will Be Eligible for TAVR Procedure. CLEARWATER, Fla., Oct. 19, 2012 /PRNewswire-USNewswire/ -- Morton Plant Hospital is the first hospital in the Tampa Bay area to perform Transcatheter Aortic Valve Replacement (TAVR) by the transapical approach. Transapical TAVR is the latest FDA-approved treatment for people suffering from severe aortic stenosis. Aortic stenosis is a narrowing of the aortic valve of the heart, which causes the valve to fail to open...
